SCM
Soleus Capital Management Portfolio holdings
AUM
$2.36B
1-Year Est. Return
93.5%
This Fund
S&P 500
1 Year Est. Return
+93.5%
AUM
$2.36B
AUM Growth
+$486M
(+26%)
Holding
120
Top Buys
| 1 | +$83.9M | |
| 2 | +$54M | |
| 3 | +$51.7M | |
| 4 |
Insulet
PODD
|
+$46.9M |
| 5 |
Alkermes
ALKS
|
+$39.6M |
Top Sells
| 1 | +$183M | |
| 2 | +$92.4M | |
| 3 | +$83.9M | |
| 4 |
CDTX
Cidara Therapeutics
CDTX
|
+$73.5M |
| 5 |
United Therapeutics
UTHR
|
+$41.9M |
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
101
Establishment Labs
ESTA
$2.09B
| – | – |
-139,512
|
|
||
102
Eton Pharmaceutcials
ETON
$462M
| – | – |
-200,000
|
|
||
|
CBIO
103
Crescent Biopharma
CBIO
$345M
| – | – |
-200,000
|
|
||
104
Grifois
GRFS
$5.85B
| – | – |
-2,500,000
|
|
||
105
Harrow
HROW
$1.34B
| – | – |
-85,498
|
|
||
106
Integra LifeSciences
IART
$771M
| – | – |
-1,440,818
|
|
||
107
IDEAYA Biosciences
IDYA
$2.9B
| – | – |
-100,000
|
|
||
108
Immunic
IMUX
$134M
| – | – |
-1,580,007
|
|
||
109
Iovance Biotherapeutics
IOVA
$1.89B
| – | – |
-976,707
|
|
||
110
Liquidia Corp
LQDA
$3B
| – | – |
-50,000
|
|
||
111
MannKind Corp
MNKD
$872M
| – | – |
-300,000
|
|
||
|
MREO
112
Mereo BioPharma
MREO
$62.2M
| – | – |
-299,711
|
|
||
113
Myomo
MYO
$32.3M
| – | – |
-704,275
|
|
||
114
uniQure
QURE
$663M
| – | – |
-200,000
|
|
||
115
Verastem
VSTM
$463M
| – | – |
-935,909
|
|
||
116
VistaGen Therapeutics
VTGN
$24.3M
| – | – |
-550,000
|
|
||
117
State Street SPDR S&P Biotech ETF
XBI
$8.12B
| – | – |
0
|
|
||
|
RAPP
118
Rapport Therapeutics
RAPP
$1.41B
| – | – |
-80,000
|
|
||
|
TECX
119
Tectonic Therapeutic
TECX
$523M
| – | – |
-25,000
|
|
||
|
CBLL
120
CeriBell Inc
CBLL
$673M
| – | – |
-360,000
|
|